To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of vaccines to prevent, treat, or mitigate opioid, cocaine, methamphetamine, or alcohol use disorder, to establish an x-prize for the development of such a vaccine, and for other purposes.
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™This bill proposes amendments to the Federal Food, Drug, and Cosmetic Act aimed at encouraging the development of vaccines to prevent, treat, or mitigate substance use disorders related to opioids, cocaine, methamphetamine, or alcohol. It includes provisions to establish an X-prize competition to incentivize innovation in vaccine development for these disorders. The bill was introduced in the House during the 118th Congress but was referred to the Subcommittee on Health and ultimately failed or expired without further legislative action.
The bill sought to promote vaccine development for substance use disorders through regulatory amendments and financial incentives but did not advance beyond subcommittee referral and expired.
- Amends the Federal Food, Drug, and Cosmetic Act to support vaccine development targeting opioid, cocaine, methamphetamine, and alcohol use disorders.
- Establishes an X-prize competition as a financial incentive to encourage innovation in vaccine development for these disorders.
- The bill was referred to the House Subcommittee on Health but did not progress further and is currently classified as failed or expired.
['Individuals affected by opioid, cocaine, methamphetamine, or alcohol use disorders who may gain access to new vaccine-based treatments.', 'Pharmaceutical and biotechnology companies engaged in vaccine research and development.', 'Public health agencies and healthcare providers focused on substance use disorder prevention and treatment.']
['Implementation challenges related to establishing and managing the X-prize competition and ensuring effective regulatory amendments.', 'Potential costs associated with administering the prize and supporting vaccine development initiatives.', 'Oversight mechanisms for prize award criteria, vaccine safety, and efficacy standards are not detailed in the available information.']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It did not advance beyond this stage and is currently designated as failed or expired. The legislative effort reflects ongoing public health concerns about substance use disorders and interest in innovative treatment approaches.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential acceleration of vaccine research and development in the substance use disorder treatment field.', 'Increased public and private sector collaboration due to financial incentives.', 'Possible shifts in public health strategies toward vaccine-based prevention and treatment modalities.']
The bill lacks publicly available full text and official summary, limiting detailed analysis. Oversight provisions, funding specifics, and regulatory changes are not fully described, which are critical for transparency and accountability. Monitoring the management of the X-prize and regulatory amendments would be important if the bill or similar legislation advances.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.